NEW YORK — Smoking is increasing among pregnant women with depression in the United States, according to new research at Columbia University’s Mailman School of Public Health and the City University of New York. Smoking rates for pregnant women with depression climbed 2.5 percent from 2002 to 2014, in contrast to a decrease among other groups. The results of the study appear online in the journal Drug and Alcohol Dependence.
The researchers evaluated rates of cigarette use among more than 8,500 pregnant women enrolled in the National Study on Drug Use and Health, an annual cross-sectional survey of the U.S. population.
Despite national trends showing a continuing decline in cigarette use over the past decade, there was no overall decline in smoking during pregnancy in the U.S. except for a slight drop in rates among pregnant women without depression. More than one-third of pregnant women with depression smoke cigarettes compared to one out of 10 pregnant women without depression.
“An increase in smoking rates in any population is concerning given the general overall downward trends we are seeing today,” said Renee Goodwin, PhD, of the Department of Epidemiology, Mailman School of Public Health, who led the research.
“The strength of the relationship between depression and prenatal smoking has increased over time, suggesting that depression is an increasingly important—but rarely treated—barrier to quitting smoking,” added Goodwin. “Smoking during pregnancy is disproportionately common among women with lower levels of education, lower income, and who are unmarried, relative to those with higher education and income. Notably, these are also groups who often have less access to prenatal care.”
“Many women may not realize that depression is interfering with their ability to stop smoking and may need extra assistance quitting,” suggested Goodwin. “Public health campaigns to educate people about the importance of quitting smoking during pregnancy is highly recommended. Treatment for depression in conjunction with smoking cessation efforts may also be the critical component to help women succeed in quitting.”
Co-authors are: Melanie Wall and Deborah Hasin, Columbia University’s Mailman School of Public Health; Keely Cheslack-Postava, Columbia University Medical Center; Phil Smith and Yoko Nomura, City University of New York; Deborah Nelson, Temple University; and Sandro Galea, Boston University School of Public Health.
The study was supported by the National Institute on Drug Abuse (DA-20892).
Columbia University’s Mailman School of Public Health
Founded in 1922, Columbia University’s Mailman School of Public Health pursues an agenda of research, education, and service to address the critical and complex public health issues affecting New Yorkers, the nation and the world. The Mailman School is the third largest recipient of NIH grants among schools of public health. Its over 450 multi-disciplinary faculty members work in more than 100 countries around the world, addressing such issues as preventing infectious and chronic diseases, environmental health, maternal and child health, health policy, climate change & health, and public health preparedness. It is a leader in public health education with over 1,300 graduate students from more than 40 nations pursuing a variety of master’s and doctoral degree programs. The Mailman School is also home to numerous world-renowned research centers including ICAP and the Center for Infection and Immunity. For more information, please visit www.mailman.columbia.edu.